|  |
| --- |
| **Supplementary table 1.** **Tuberculin skin test (TST) and QuantiFERON® TB Gold Test-in-tube (QFT-GIT) results among fifty-two “resisters” household contacts (HHCs) in India** |
| **TST and QFT-GIT characteristic at baseline and follow up** | **Overall****N=52** | **Children** **< 6 years****N=14** | **Children****6-<15 years****N=21** | **Adults and adolescents****>15 years****N=17** |
| **No response to TST or QFT-GIT**  |
| TST - 0mm or QFT-GIT < 0.01 (IU/mL) (N=52) | 27 (53%) | 9 (17%) | 9 (17%) | 9 (17%) |
| TST - 0 mm (N=37) | 13 (35%) | 4 (31%) | 6 (46%) | 3 (23%) |
| QFT-GIT < 0.01 (IU/mL)(N=44) | 14 (32%) | 5 (36%) | 3 (21%) | 6 (43%) |
| \*TST - 0mm and QFT-GIT < 0.01 (IU/mL)(N=15) | 0  | - | - | - |
| **Other resisters** |
| TST - 1mm - 4mm or QFT-GIT - 0.01 IU/mL - 0.34 IU/mL(N=52) | 14 (27%) | 4 (29%) | 4 (29%)  | 6 (42%) |
| TST - 1mm - 4mm(N=37) | 8 (22%) | 3 (38%) | 1 (12%) | 4 (50%) |
| QFT-GIT - 0.01 IU/mL - 0.34 IU/mL(N=44) | 6 (14%) | 1 (17%) | 3 (50%) | 2 (33%) |
| \*TST - 1mm - 4mm and QFT-GIT - 0.01 IU/mL - 0.34 IU/mL(N=15) | 1 (2%) | - | - | 1 (100%) |
| “Resisters” are defined as HHCs with no evidence of LTBI in 12 months following exposure to culture-confirmed pulmonary TB despite high TB exposure (defined as >6 score for adults and >5 score for children using Mandalakas score [6]) \*represents both TST and QFT-GIT was performed at entry, 4 and 12 months among 52 resisters. |